RPRX — Royalty Pharma Income Statement
0.000.00%
Last trade - 00:00- $26.74bn
- $37.44bn
- $2.38bn
Annual income statement for Royalty Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,289 | 2,237 | 2,355 | 2,264 | 2,378 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 859 | 1,930 | 862 | 971 | 819 |
| Operating Profit | 1,431 | 307 | 1,492 | 1,292 | 1,560 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1,241 | 230 | 1,700 | 1,331 | 1,324 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1,241 | 230 | 1,700 | 1,331 | 1,324 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 620 | 42.8 | 1,135 | 859 | 771 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 620 | 42.8 | 1,528 | 1,136 | 1,006 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.49 | 1.5 | 2.53 | 1.91 | 1.78 |
| Dividends per Share |